Company profile
Grey Wolf Therapeutics - Next Generation Immuno-oncology
By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the neoantigen repertoire in cancer.
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ0MjU2MjI1OWFkaXF6a2N4
Published 12 Nov 2024 04:59
RESOLUTIONS | Transaction WUREVEg0SVhhZGlxemtjeA | Paper/PDF filed
Published 24 Oct 2024 07:09
MA | Transaction MzQzOTc5NjIxOGFkaXF6a2N4 | Paper/PDF filed
Published 24 Oct 2024 06:54
AA | Transaction MzQzMzgwMzE5OGFkaXF6a2N4
Published 29 Aug 2024 11:30
Company registered at Companies House
1 Aug 2024 to 30 Nov 2025
Cancer is the leading cause of death worldwide, with the global economic cost of cancer estimated at £930 billion in 2021\. In the UK, 1 in ~18 people will be diagnosed with colorectal cancer(CRC) in their lifetime. Microsatellite-stable CRC (MSS-CRC) represents ~85% of all CRC cases and 95% of advanced metastatic CRC(mCRC) which has a very low 5-year sur...
1 Mar 2021 to 31 Aug 2022
Grey Wolf Therapeutics is developing a next-generation approach to cancer immunotherapy that is more effective than existing treatments and can be applied to a much wider variety of cancers. Breakthroughs in immunotherapy have been ground-breaking in the treatment of some cancers, with great benefits in some patients with advanced disease, in some cases e...
